From one sinking ship to another?

It’s not very often that you see a pharmaceutical company completely giving up on a drug that’s already won regulatory approval and has reached the market – at least not without uncovering some serious side effect that didn’t show up in the clinical trials. With many of the difficult, risky parts of the process already traversed, it should be time to sell some product and recoup some investments. And you wouldn’t have put all that effort into a product that you didn’t believe was going to be able to do that, naturally.